Search

Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is still needed, and targeted alpha therapy (TAT) with alpha emitters such as lead-212 (212Pb) represents a promising avenue. A series of ligands based on octreotate was developed. Lead-203 was used as an imaging surrogate for the selection of the best candidate for the studies with lead-212. 203/212Pb radiolabeling and in vitro assays were carried out, followed by SPECT/CT imaging and ex vivo biodistribution in NCI-H69 tumor-bearing mice. High radiochemical yields (≥99%) and purity (≥96%) were obtained for all ligands. [203Pb]Pb-eSOMA-01 and [203Pb]Pb-eSOMA-02 showed high stability in PBS and mouse serum up to 24 h, whereas [203Pb]Pb-eSOMA-03 was unstable in those conditions. All compounds exhibited a nanomolar affinity (2.5–3.1 nM) for SSTR2. SPECT/CT images revealed high tumor uptake at 1, 4, and 24 h post-injection of [203Pb]Pb-eSOMA-01/02. Ex vivo biodistribution studies confirmed that the highest uptake in tumors was observed with [212Pb]Pb-eSOMA-01. [212Pb]Pb-eESOMA-01 displayed the highest absorbed dose in the tumor (35.49 Gy/MBq) and the lowest absorbed dose in the kidneys (121.73 Gy/MBq) among the three tested radioligands. [212Pb]Pb-eSOMA-01 is a promising candidate for targeted alpha therapy of NETs. Further investigations are required to confirm its potential.

The coordination of the antimetastatic agent NAMI-A, [H(2)im][trans-RuCl(4)(dmso-S)(Him)], (Him=imidazole; dmso=dimethyl sulfoxide), to the DNA model base 9-methyladenine (9-MeAde) was investigated in water. NMR spectroscopy was first applied for the study of the molecular stability and hydrolysis of NAMI-A in aqueous solution over a range of pH (3.0-7.4) and chloride ion concentrations (0-1 M) at 37.0 degrees C. In physiological conditions (phosphate buffer, pH 7.4) NAMI-A disappears from the solution in 15 min due to chloride and dmso hydrolysis, leading to uncharacterised poly-oxo Ru species. Conversely, at lower pH (3.0-6.0) and in water (pH approximately 5.5), only a partial dmso hydrolysis occurs, slowly forming the [trans-RuCl(4)(H(2)O)(Him)](-) complex. This latter species coordinates to 9-MeAde (via the N7 of 9-MeAde), forming the [trans-RuCl(4)(9-MeAde)(Him)](-) complex. NAMI-A and [trans-RuCl(4)(H(2)O)(Him)](-) give comparable intracellular ruthenium concentrations and accumulate in KB cells (human mouth carcinoma) and accumulate these at the G(2)/M phase, while poly-oxo Ru species do not, and their cell uptake is reduced to 50%. On the contrary, G(2)/M arrest and protein content in the murine metastatic cell line metGM, are not influenced by NAMI-A hydrolysis. Hydrolysed NAMI-A species apparently are easier taken up by the metGM cells, showing intracellular ruthenium concentrations one order of magnitude greater than those of intact NAMI-A. Therefore, it is proposed that the selective antimetastatic activity of NAMI-A during in vivo experiments can be attributed to its hydrolysed species.

The coordination of the DNA model base 9-methyladenine (9-MeAde) to both complexes cis-[Ru(bpy)2Cl2] and α-[Ru(azpy)2(NO3)2] is reported. Structural characterisation using 2D NMR techniques and variable-temperature NMR studies between 25 and −55 °C show that in the compounds α-[Ru(azpy)2(9-MeAde)](PF6)2 (1) and cis-[Ru(bpy)2(9-MeAde)](PF6)2 (2), 9-MeAde is coordinated to the ruthenium ion in a chelating mode via its N7 and exocyclic N6 atoms. The NMR spectroscopic data unambiguously prove the occurrence of the rare imine tautomer of 9-MeAde in these complexes, which is clearly stabilised by the bidentate coordination of 9-MeAde in both complexes. Variable-temperature NMR spectra and 2D COSY data show that the H2 resonance of 9-MeAde in 1 and 2 appears as a doublet at low temperatures and shows a COSY cross peak to the NH1 resonance of 9-MeAde, which confirms the protonation at the N1 site. This protonated N1 site, together with an observed pKa of ca. 6.5 of compound 1 is in agreement with the presence of the imine tautomeric form of 9-MeAde. As the binding mode of 9-MeAde to both cis-[Ru(bpy)2] and α-[Ru(azpy)2] moieties is the same, this binding mode does not explain the earlier observed difference in cytotoxicity between cis-[Ru(bpy)2Cl2] and α-[Ru(azpy)2Cl2].

The DNA-cleavage ability of novel bifunctional heterobimetallic copper-ruthenium complexes is demonstrated by using gel electrophoresis.

The reaction of copper(II) perchlorate with the macrocyclic ligand [22]py4pz in the presence of base leads to formation of a dinuclear complex [Cu(2)([22]py4pz)(mu-OH)](ClO(4))(3)xH(2)O, in which two copper ions are bridged by a single mu-hydroxo bridge. Each copper ion is further surrounded by four nitrogen atoms of the ligand. The mu-hydroxo bridge mediates a strong antiferromagnetic coupling (2J = -691(35) cm(-1)) between the metal centers, leading to relatively sharp and well-resolved resonances in the (1)H NMR spectrum of the complex in solution. We herein report the crystal structure, the magnetic properties, and the full assignment of the hyperfine-shifted resonances in the NMR spectrum of the complex, as well as the determination of the exchange coupling constant in solution through temperature-dependent NMR studies.